Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
By M. Tohen, Eduard Vieta, J. Calabrese, T. Ketter, G. Sachs, C. Bowden, P. Mitchell, F. Centorrino, R. Risser, R. Baker and 5 more. Archives of General Psychiatry, 2003
854 citations recorded by the source corpus.
Subfields: Biological Psychiatry, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/189e68ab395ef3e9a37f224c50fda41588dacec5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biological Psychiatry
In Pharmacology
In Psychiatry and Mental health
Citations in the corpus
- A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. (2005, methodology): “More recently, the atypical antipsyChotic olanzapine was found to be superior to placebo in the treatment of acute bipolar I depression as monotherapy when data were pooled from two 8-week trials (14).”
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (2013, background): “In addition, a post-hoc analysis of a previously cited combination study (95) found that both OFC and olanzapine monotherapy were more efficacious than placebo in patients with BD I mixed depression (i.”
- The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders (2013, background): “these (24) compared the efficacy and safety of olanzapine”
- Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, neutral): “Interest in the use of dopamine antagonists or partial agonists as monotherapy began when a large RCT showed that olanzapine had a weak antidepressant effect in bipolar I depression compared with placebo (Tohen et al., 2003).”
- Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “Randomised controlled trials report that olanzapine (Tohen et al., 2003c, 2012), quetiapine (Calabrese et al., 2005b; McElroy et al., 2010; Thase, 2006; Young et al., 2010) and lurasidone (Loebel et al., 2014a, 2014b) are effective treatments for bipolar depression, but these studies have…”